#####################
# Document Metadata #
#####################
SET DOCUMENT Name = "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-b peptide and s levels: target engagement, tolerability and pharmacokinetics in humans"
SET DOCUMENT Version = "0.1.0"
SET DOCUMENT Authors = "Lingling Xu"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"
SET DOCUMENT Description = "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-b peptide and s levels: target engagement, tolerability and pharmacokinetics in humans by Macccecchini, et al., 2012"

##############
# Namespaces #
##############

DEFINE NAMESPACE HBP   AS URL "https://raw.githubusercontent.com/pharmacome/terminology/3c85897632afa791ac78fb3aa2e392963ab155b1/export/hbp-names.belns"
DEFINE NAMESPACE CHEBI AS URL "https://raw.githubusercontent.com/pharmacome/terminology/9a77ac1a02863bc48b04bab7e8fb0c1d1cec4dd0/external/chebi.belns"
DEFINE NAMESPACE GO    AS URL "https://raw.githubusercontent.com/pharmacome/terminology/9a77ac1a02863bc48b04bab7e8fb0c1d1cec4dd0/external/go.belns"

DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"
###############
# Annotations #
###############

DEFINE ANNOTATION MeasurementType AS LIST {"IC50","plasma concentration","brain concertration", "CSF concentration","dose"}
DEFINE ANNOTATION MeasurementUnits AS LIST {"μM","mg"}
DEFINE ANNOTATION MeasurementRelation AS LIST {"=", "~"}
DEFINE ANNOTATION MeasurementValue AS PATTERN ".*"
DEFINE ANNOTATION MeasurementRangeLower AS PATTERN ".*"
DEFINE ANNOTATION MeasurementRangeUpper AS PATTERN ".*"

DEFINE ANNOTATION Page AS PATTERN ".*"
DEFINE ANNOTATION Figure AS PATTERN ".*"
DEFINE ANNOTATION ArticleCompoundNumber AS PATTERN ".*"

#######################################################################################################################################################################
# Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans #
#######################################################################################################################################################################
SET Citation = {"PubMed", "22791904"}

SET Page = 896
SET Evidence ="A 160 mg dose was associated with an increased incidence of nausea and vomiting (four subjects were nauseous and three vomited)"
SET Figure = 2A
SET ArticleCompoundNumber = 1
SET MeasurementType = "dose"
SET MeasurementUnits ="mg"
SET MeasurementValue =160

a(PUBCHEM:"11249342") -> path(MESH:Nausea)
a(PUBCHEM:"11249342") -> path(MESH:Vomiting)

UNSET {MeasurementValue,MeasurementUnits,MeasurementType,ArticleCompoundNumber,Figure}


SET Evidence ="Posiphen 80 mg was determined as the no observed adverse effect level (table 1)."
SET ArticleCompoundNumber = 1
SET MeasurementType = "dose"
SET MeasurementUnits ="mg"
SET MeasurementValue =80

a(PUBCHEM:"11249342") cnc path(MESH:Nausea)
a(PUBCHEM:"11249342") cnc path(MESH:Vomiting)
UNSET {MeasurementValue,MeasurementUnits,MeasurementType,ArticleCompoundNumber,Page}

SET Evidence ="The four times a day regimen resulted in some accumulation of Posiphen in plasma and accumulation of Posiphen/metabolites in CSF"

SET Page =899
SET Evidence ="Specifically, Posiphen lowered sAPPa and sAPPb levels by 59.9% and 57.7%, respectively, assessed by the AlpaLisa assay, and by 34.1% and 34%, respectively, assessed by the MSD assay, in accordance with Posiphen’s proposed mechanism of action to inhibit APP expression."
SET ArticleCompoundNumber = 1
a(PUBCHEM:"11249342") -| a(HBP:sAPP-alpha)
a(PUBCHEM:"11249342") -| a(HBP:sAPP-beta)

SET Evidence ="In addition, Posiphen significantly reduced levels of t-s (74.1%, as assessed by the Innogenetics assay and 46.2%, as assessed by the AlphaLisa assay) and p-s (61%, as assessed by the Innogenetics assay)."
a(PUBCHEM:"11249342") -| p(HGNC:MAPT)
a(PUBCHEM:"11249342") -| p(HGNC:MAPT,pmod(Ph))

SET Evidence =" A significant lowering of pro-inflammatory, C3 (86.9%) and microglial activation markers, MCP-1 (87.5%) and YKL-40 (72.7%), was evident."
a(PUBCHEM:"11249342") -| p(HGNC:C3)
a(PUBCHEM:"11249342") -| p(HGNC:CCL2)
a(PUBCHEM:"11249342") -| p(HGNC:CHIL1)

SET Evidence ="and the complement control protein, factor H, were unaffected by Posiphen (26.1% and +23.7%, respectively)."
a(PUBCHEM:"11249342") cnc p(HGNC:CFH)

UNSET Page
UNSET Citation
